Summit Therapeutics Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antibiotics for serious infectious diseases. Its lead CDI product candidate is ridinilazole is an orally administered small molecule antibiotic. The Company’s preclinical candidates include SMT-738, from the DDS-04 series for development in the fight against multidrug-resistant infections, specifically carbapenem-resistant Enterobacteriaceae (CRE) infections. The Company is conducting a Phase III clinical program, which is focused on treating patients suffering from Clostridioides difficile infection, also known as C. difficile infection (CDI). The Company is also seeking to expand its product candidate portfolio through the development of a new mechanism, precision antibiotics using its Discuva Platform.